Appili Therapeutics (APLIF) announced the United States Patent and Trademark Office and the Mexican Patent Office have granted new patent claims protecting its oral formulation of metronidazole, LIKMEZ. The newly granted patents include: U.S. patent no. 20230086660A1 – Oral Formulations of Metronidazole and Methods of Treating an Infection Using Same; Mexican patent no. 2020007494 – Oral Formulations of Metronidazole and Methods of Treating an Infection Using Same. The two new patents, set to expire in 2039 provide comprehensive protection for LIKMEZ, covering its unique taste masked composition and accessible therapeutic applications.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLIF:
- Appili Therapeutics CEO to Discuss Strategic Growth and Funding Initiatives
- Appili Therapeutics CEO to join Aditxt CEO for weekly update on April 4
- Biotech Alert: Searches spiking for these stocks today
- Appili Therapeutics Seeks $117.5 Million in Federal Funding for Infectious Disease Treatments
- Appili Therapeutics announces submission of government funding proposals